We are live on ! Find out more
UNCY icon

Unicycive Therapeutics

23 hedge funds and large institutions have $9.52M invested in Unicycive Therapeutics in 2024 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 2323 (0)

0% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 5

0% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 6

1.06% less ownership

Funds ownership: 6.11%5.05% (-1.1%)

70% less capital invested

Capital invested by funds: $31.6M → $9.52M (-$22.1M)

Holders
23
Holders Change
Holders Change %
0%
% of All Funds
0.33%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
5
Increased
6
Reduced
6
Closed
5
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
GSC
26
Ground Swell Capital
South Carolina
-$26.4K -1,912 Closed
IWC
27
Integrated Wealth Concepts
Massachusetts
-$13.8K -1,000 Closed
Wells Fargo
28
Wells Fargo
California
-$270 -20 Closed

UNCY Hedge Fund Activity: Q2 2024 in Review

23 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Unicycive Therapeutics (UNCY) for Q2 2024, worth a combined $9.52M — down 70% from $31.6M a quarter earlier.

Fund positioning in UNCY was balanced in Q2 2024: 5 funds opened new positions, 5 closed out, 6 added to existing stakes and 6 trimmed.

The largest buyer was Vanguard Group, adding an estimated $785K. The largest seller was BVF Inc, cutting an estimated $1.39M.

  • 23 institutional investors held Unicycive Therapeutics (UNCY) as of Q2 2024, unchanged from Q1 2024.
  • Funds reported $9.52M of Unicycive Therapeutics stock for Q2 2024, down 70% quarter-over-quarter.
  • 5 funds opened new Unicycive Therapeutics positions in Q2 2024 and 5 closed out, a net change of 0 holders.
  • The largest Unicycive Therapeutics buyer in Q2 2024 was Vanguard Group, an estimated $785K added.
  • The largest Unicycive Therapeutics seller in Q2 2024 was BVF Inc, an estimated $1.39M sold.

Based on aggregated 13F filings for Q2 2024.